$ cat ./records/gates-foundation-convenes-global-maternal-immunization-research-m-2015.txt
Gates Foundation Convenes Global Maternal Immunization Research Meeting in Berlin
[RECORD.TXT] · cat --full
The Gates Foundation convened an international stakeholder meeting in Berlin bringing together funders, academics, regulatory agencies, NGOs, vaccine manufacturers, and health ministries from sub-Saharan Africa and South Asia to prioritise and coordinate maternal immunisation research. The gathering focused on vaccines protecting mothers and newborns from Group B Streptococcus, respiratory syncytial virus (RSV), and influenza, and produced a roadmap for clinical development that informed subsequent investments across the field.
Source: https://www.sciencedirect.com/science/article/pii/S0264410X15011743
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Invests in Carbon Engineering Direct Air Capture Startup
Next →
Gates Foundation Commits $52 Million to CureVac mRNA Platform
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.